சனி, 21 ஜனவரி, 2017

Sclerostin levels not associated with type 2 diabetes risk


The risk for type 2 diabetes is not significantly associated with sclerostin levels, but weak correlations exist between sclerostin and fasting glucose and insulin levels and homeostasis model of assessment for insulin resistance, according to study results.

Oriana Hoi Yun Yu, MD, MSc, of the Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital and the division of endocrinology, Jewish General Hospital in Montreal, and colleagues evaluated data from the population-based Canadian Multicentre Osteoporosis Study on 1,778 adults (mean age, 63.2 years) with no history of type 2 diabetes. Researchers sought to determine whether sclerostin levels are associated with fasting glucose and insulin levels, insulin resistance or the risk for type 2 diabetes. Follow-up was conducted until Dec. 31, 2013, diagnosis of type 2 diabetes or death (median, 7.5 years).
Researchers observed a weak relationship between sclerostin levels and fasting glucose (P < .05) and insulin levels (P < .05) and homeostasis model of assessment for insulin resistance (HOMA-IR; P = .02). After adjustment for covariables, there was no longer a significant relationship between sclerostin and fasting glucose level (P = .97). However, sclerostin levels were associated with fasting insulin (P < .0001) and HOMA-IR (P < .0001) on multiple linear regression analysis.
Through follow-up, there was a rate of type 2 diabetes of 7.7 per 1,000 person-years.
In the primary analyses, No significant relationships were observed between sclerostin levels and the risk for incident type 2 diabetes (HR = 1.3; 95% CI, 0.37-4.57).
“This study demonstrated that sclerostin levels are not conclusively associated with the risk of incident type 2 diabetes, but showed a significant association between fasting insulin levels and sclerostin, suggesting a possible link between glucose metabolism, insulin resistance and the sclerostin pathway,” the researchers wrote. “Further studies are required to assess the directionality of effect to determine whether glucose metabolism and sclerostin are causally related.” – by Amber Cox

கருத்துகள் இல்லை:

கருத்துரையிடுக